Wednesday, January 2, 2019
Myriad Genetics initiated at Needham
Myriad Genetics initiated at Needham Myriad Genetics initiated with a Strong Buy at. Needham analyst Stephen Unger started Myriad Genetics with a Strong Buy rating and $36 price target. The analyst believes the company’s expanding portfolio of molecular diagnostic testing services and an increased focus on profit improvement can drive “significant” earnings upside.
https://thefly.com/landingPageNews.php?id=2842791
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.